Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients

Optimal care for breast cancer patients undergoing aromatase inhibitor (AI) treatment is ensured when estradiol (E(2)) levels are adequately suppressed. To assess treatment efficacy accurately, it is important to measure the serum E(2) levels using a well validated assay method with high sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaque, Jenny, Macdonald, Heather, Brueggmann, Doerthe, Patel, Sherfaraz K, Azen, Colleen, Clarke, Nigel, Stanczyk, Frank Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599208/
https://www.ncbi.nlm.nih.gov/pubmed/23520572
http://dx.doi.org/10.1186/2193-1801-2-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599208/
https://www.ncbi.nlm.nih.gov/pubmed/23520572
http://dx.doi.org/10.1186/2193-1801-2-5

Ejemplares similares